Cargando…

Targeting B-cell maturation antigen increases sensitivity of multiple myeloma cells to MCL-1 inhibition

Detalles Bibliográficos
Autores principales:	Cuenca, Marta, van Nieuwenhuijzen, Niels, Moesbergen, Laura M., Bloem, Andries, Minnema, Monique C., Peperzak, Victor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2021
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968894/ https://www.ncbi.nlm.nih.gov/pubmed/34879645 http://dx.doi.org/10.3324/haematol.2021.279517

Ejemplares similares

Phosphatase PP2A enhances MCL-1 protein half-life in multiple myeloma cells
por: Slomp, Anne, et al.
Publicado: (2021)

Wnt inhibitors reduce the unfolded protein response and enhance bortezomib-induced cell death in multiple myeloma
por: Spaan, Ingrid, et al.
Publicado: (2022)

Therapeutic outcome of early-phase clinical trials in multiple myeloma: a meta-analysis
por: van Nieuwenhuijzen, Niels, et al.
Publicado: (2021)

MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL
por: Vikström, Ingela B, et al.
Publicado: (2016)

Advances and Perspectives in the Treatment of B-Cell Malignancies
por: Cuenca, Marta, et al.
Publicado: (2021)

Role and Regulation of Pro-survival BCL-2 Proteins in Multiple Myeloma
por: Slomp, Anne, et al.
Publicado: (2018)

Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma
por: Fang, Yi, et al.
Publicado: (2021)

Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma
por: Al-Odat, Omar S., et al.
Publicado: (2021)

Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma
por: Ma, Tiantian, et al.
Publicado: (2019)

Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
por: Timmers, Marijke, et al.
Publicado: (2019)

CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond
por: Mishra, Abhinava K., et al.
Publicado: (2023)

Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2022)

Role of Anti-B-Cell Maturation Antigen (BCMA) in the Management of Multiple Myeloma
por: Rinaldi, Ikhwan, et al.
Publicado: (2022)

Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives
por: Shrivastava, Trilok, et al.
Publicado: (2023)

Soluble B-cell maturation antigen as a monitoring marker for multiple myeloma
por: Wiedemann, Ádám, et al.
Publicado: (2023)

Erratum: Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma
Publicado: (2021)

Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells
por: De Veirman, Kim, et al.
Publicado: (2015)

The exploration of B cell maturation antigen expression in plasma cell dyscrasias beyond multiple myeloma
por: Xu, Yanjie, et al.
Publicado: (2023)

B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies
por: Sanchez, Larysa, et al.
Publicado: (2021)

B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages
por: Nobari, Shirin Teymouri, et al.
Publicado: (2022)

Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential
por: Spaan, Ingrid, et al.
Publicado: (2018)

Preclinical development of a humanized chimeric antigen receptor against B-cell maturation antigen for multiple myeloma
por: Perez-Amill, Lorena, et al.
Publicado: (2020)

Serpin B9 controls tumor cell killing by CAR T cells
por: Kimman, Thomas, et al.
Publicado: (2023)

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
por: Shah, Nina, et al.
Publicado: (2020)

PB2104: SOLUBLE B-CELL MATURATION ANTIGEN AS A MONITORING MARKER FOR MULTIPLE MYELOMA
por: Wiedemann, Ádám, et al.
Publicado: (2023)

Toward targeting B cell cancers with CD4(+) CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis
por: Spaapen, Robbert M., et al.
Publicado: (2008)

Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma
por: Bu, De-Xiu, et al.
Publicado: (2018)

Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma
por: Bilich, Tatjana, et al.
Publicado: (2020)

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
por: Cho, Shih-Feng, et al.
Publicado: (2018)

Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
por: Ghermezi, Michael, et al.
Publicado: (2017)

Infusion of chimeric antigen receptor T cells against dual targets of CD19 and B-cell maturation antigen for the treatment of refractory multiple myeloma
por: Tang, Fang, et al.
Publicado: (2020)

Nursing care of patients with relapsed and refractory multiple myeloma treated with B-cell mature antigen-targeted universal chimeric antigen receptor T cells
por: Dai, Ying, et al.
Publicado: (2023)

Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients
por: Bera, T K, et al.
Publicado: (2018)

Development of a T cell-redirecting bispecific antibody targeting B-cell maturation antigen for the suppression of multiple myeloma cell growth
por: Huo, Jianxin, et al.
Publicado: (2022)

Silence of MCL-1 upstream signaling by shRNA abrogates multiple myeloma growth
por: Wang, Mengchang, et al.
Publicado: (2014)

B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma
por: Abramson, Hanley N.
Publicado: (2020)

Study on the Relationship Between the Expression of B Cell Mature Antigen and the Classification, Stage, and Prognostic Factors of Multiple Myeloma
por: Ma, Tiantian, et al.
Publicado: (2021)

Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment
por: Baljevic, Muhamed, et al.
Publicado: (2022)

Multiple Myeloma Relapse Is Associated with Increased NFκB Pathway Activity and Upregulation of the Pro-Survival BCL-2 Protein BFL-1
por: Spaan, Ingrid, et al.
Publicado: (2021)

Protracted viral infections in patients with multiple myeloma receiving bispecific T-cell engager therapy targeting B-cell maturation antigen
por: Palmen, Breanna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rsv7hm07ij2c5a2rmbrrdt6j2a